{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:43:14Z","timestamp":1766086994215,"version":"3.37.3"},"reference-count":100,"publisher":"National Institute for Health and Care Research","issue":"65","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000276","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["10\/12\/01"],"award-info":[{"award-number":["10\/12\/01"]}],"id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"Background<\/jats:title>Optimal therapy for children with chronic hepatitis C is unclear. Two treatment regimens are currently licensed in children.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To assess the clinical effectiveness and cost-effectiveness of peginterferon alfa-2a (Pegasys\u00ae<\/jats:sup>, Roche) and peginterferon alfa-2b [ViraferonPeg\u00ae<\/jats:sup>, Merck Sharp & Dohme (MSD)] in combination with ribavirin (RBV), within their licensed indications, for the treatment of chronic hepatitis C virus (HCV) in children and young people aged 3\u201317 years.<\/jats:p><\/jats:sec>Data sources<\/jats:title>Twelve electronic bibliographic databases, including The Cochrane Library, MEDLINE and EMBASE, were searched from inception to November 2012. Bibliographies of retrieved papers, key hepatitis C websites and symposia and manufacturers\u2019 submissions to the National Institute for Health and Care Excellence were also searched, and clinical experts were contacted.<\/jats:p><\/jats:sec>Review methods<\/jats:title>Systematic reviews of clinical effectiveness and cost-effectiveness were conducted, including studies of health-related quality of life (HRQoL), following standard guidelines to ensure methodological rigour. Clinical effectiveness studies were included if they were in children and young people aged 3\u201317 years with chronic compensated HCV of any severity, including those with human immunodeficiency virus co-infection and those who were treatment naive or had been previously treated. Eligible interventions were peginterferon alfa-2a or peginterferon alfa-2b, each in combination with RBV, compared against best supportive care (BSC) or against each other, and study designs were randomised controlled trials (RCTs) or non-RCTs, or uncontrolled cohort studies. Outcomes included sustained virological response (SVR) and adverse events. Previously published Markov state-transition economic models of chronic HCV in adults were adapted to estimate the cost-effectiveness of peginterferon alfa-2a and -2b (in combination with RBV), compared with BSC and with one another in children. The model extrapolated the impact of SVR on life expectancy, quality-adjusted life expectancy and lifetime costs. Uncertainty was explored through probabilistic and deterministic sensitivity analyses.<\/jats:p><\/jats:sec>Results<\/jats:title>Seven studies [two peginterferon alfa-2a and RBV (Copegus\u00ae<\/jats:sup>, Roche), and five peginterferon alfa-2b and RBV (Rebetol\u00ae<\/jats:sup>, MSD)] were included in the review of clinical effectiveness. Six were single-arm cohort studies and one was a RCT for which only those data for a single arm met the inclusion criteria. Overall, the studies were relatively small and of generally poor quality. SVR rates ranged from 53% to 66% (peginterferon alfa-2a) and 29% to 75% (peginterferon alfa-2b) (49% to 65% if excluding two studies with very small sample sizes). Rates of non-response and relapse were variable and adverse events were generally mild. No studies of cost-effectiveness or HRQoL in children and young people met the inclusion criteria. HRQoL, utilities and costs of treatment were therefore taken from studies of adults with chronic HCV. From this model, peginterferon alfa (-2a or -2b) in combination with RBV was more effective and had lower lifetime costs than BSC. Peginterferon alfa-2a had slightly lower lifetime costs and higher quality-adjusted life-years than peginterferon alfa-2b; therefore, peginterferon alfa-2b was dominated by peginterferon alfa-2a. Results were robust to changes in the sensitivity analyses.<\/jats:p><\/jats:sec>Limitations<\/jats:title>There were few good quality studies and parameter data had to be taken from adult studies, which is a limitation of the work.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Treatment of children and young people with peginterferon (alfa-2a or -2b) and RBV may be an effective therapy. Results from the independent Markov model suggest that peginterferon (alfa-2a or -2b) in combination with RBV is cost-effective compared with BSC. However, the available evidence is of poor quality. Future research into the impact of these treatments on growth and quality of life in children and young people is recommended.<\/jats:p><\/jats:sec>Study registration<\/jats:title>This study is registered as PROSPERO CRD42012002743.<\/jats:p><\/jats:sec>Funding<\/jats:title>The National Institute for Health Research Health Technology Assessment programme.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta18650","type":"journal-article","created":{"date-parts":[[2014,10,30]],"date-time":"2014-10-30T09:02:33Z","timestamp":1414659753000},"page":"1-202","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation"],"prefix":"10.3310","volume":"18","author":[{"given":"Debbie","family":"Hartwell","sequence":"first","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Cooper","sequence":"additional","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoff K","family":"Frampton","sequence":"additional","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Baxter","sequence":"additional","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Loveman","sequence":"additional","affiliation":[{"name":"Southampton Health Technology Assessments Centre (SHTAC), University of Southampton, Southampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6221","published-online":{"date-parts":[[2014,10]]},"reference":[{"key":"key20141028145853201_ref1-bib1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1469-0691.2004.01061.x","article-title":"Hepatitis C virus infection","volume":"11","author":"Thomson","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"key20141028145853201_ref1-bib2","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1001\/jama.289.18.2413","article-title":"Chronic hepatitis C virus infection","volume":"289","author":"Flamm","year":"2003","journal-title":"JAMA"},{"volume-title":"Hepatitis C in the UK: 2008 Report","year":"2008","author":"","key":"key20141028145853201_ref1-bib3"},{"key":"key20141028145853201_ref1-bib4","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1136\/adc.2005.081877","article-title":"Perinatal hepatitis C virus infection: diagnosis and management","volume":"91","author":"Davison","year":"2006","journal-title":"Arch Dis Child"},{"key":"key20141028145853201_ref1-bib5","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MPG.0b013e3181f6f09c","article-title":"Guidance for clinical trials for children and adolescents with chronic hepatitis C","volume":"52","author":"Wirth","year":"2011","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key20141028145853201_ref1-bib6","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/j.1478-3231.2011.02633.x","article-title":"The natural history of hepatitis C virus infection acquired during childhood","volume":"32","author":"Robinson","year":"2012","journal-title":"Liver Int"},{"key":"key20141028145853201_ref1-bib7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3748\/wjg.v18.i2.99","article-title":"Current treatment options and response rates in children with chronic hepatitis C","volume":"18","author":"Wirth","year":"2012","journal-title":"World J Gastroenterol"},{"volume-title":"Hepatitis C in Children","year":"2008","author":"Roy","key":"key20141028145853201_ref1-bib8"},{"key":"key20141028145853201_ref1-bib9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1053\/jhep.2001.25885","article-title":"Mother-to-infant transmission of hepatitis C virus","volume":"34","author":"Yeung","year":"2001","journal-title":"Hepatology"},{"volume-title":"Hepatitis C in the UK: 2011 Report","year":"2011","author":"","key":"key20141028145853201_ref1-bib10"},{"key":"key20141028145853201_ref1-bib11","doi-asserted-by":"publisher","first-page":"e11542","DOI":"10.1371\/journal.pone.0011542","article-title":"Treatment of hepatitis C in children: a systematic review","volume":"5","author":"Hu","year":"2010","journal-title":"PLoS ONE"},{"key":"key20141028145853201_ref1-bib12","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1053\/j.gastro.2008.02.082","article-title":"Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease","volume":"134","author":"Bortolotti","year":"2008","journal-title":"Gastroenterology"},{"key":"key20141028145853201_ref1-bib13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1097\/MPG.0b013e3180dc9337","article-title":"A national sample of individuals who acquired hepatitis C virus infections in childhood or adolescence: risk factors for advanced disease","volume":"45","author":"Harris","year":"2007","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key20141028145853201_ref1-bib14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1086\/345908","article-title":"Chronic hepatitis C infection in childhood: clinical patterns and evolution in 224 white children","volume":"36","author":"Jara","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key20141028145853201_ref1-bib15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/01.mpg.0000228117.52229.32","article-title":"Hepatitis C in children: a quaternary referral center perspective","volume":"43","author":"Rumbo","year":"2006","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key20141028145853201_ref1-bib16","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1097\/MPG.0b013e318258328d","article-title":"NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infancts, children and adolescents","volume":"54","author":"Mack","year":"2012","journal-title":"JPGN"},{"key":"key20141028145853201_ref1-bib17","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1111\/j.1440-1746.2004.03463.x","article-title":"Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children","volume":"19","author":"Rerksuppaphol","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"key":"key20141028145853201_ref1-bib18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/j.1365-2893.2011.01128.x","article-title":"The impact of mode of acquisition on biological markers of paediatric hepatitis C virus infection","volume":"18","author":"England","year":"2011","journal-title":"J Viral Hepatitis"},{"key":"key20141028145853201_ref1-bib19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/INF.0b013e318236ac37","article-title":"Diagnosis and management of hepatitis C virus-infected children","volume":"30","author":"Jhaveri","year":"2011","journal-title":"Pediatr Infect Dis J"},{"issue":"11","key":"key20141028145853201_ref1-bib20","doi-asserted-by":"crossref","DOI":"10.3310\/hta11110","article-title":"Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation","volume":"11","author":"Shepherd","year":"2007","journal-title":"Health Technol Assess"},{"key":"key20141028145853201_ref1-bib21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/hep.1840010511","article-title":"Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis","volume":"1","author":"Knodell","year":"1981","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib22","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/0168-8278(95)80226-6","article-title":"Histological grading and staging of chronic hepatitis","volume":"22","author":"Ishak","year":"1995","journal-title":"J Hepatol"},{"key":"key20141028145853201_ref1-bib23","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/hep.510270132","article-title":"Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis","volume":"27","author":"Foster","year":"1998","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib25","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/00005176-200002000-00028","article-title":"Quality of life of patients with chronic hepatitis C virus infection","volume":"30","author":"Akobeng","year":"2000","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key20141028145853201_ref1-bib26","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1440-1746.2007.04859.x","article-title":"Health-related quality of life in children with hepatitis C acquired in the first year of life","volume":"23","author":"Nydegger","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"key20141028145853201_ref1-bib27","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/MPG.0b013e318185998f","article-title":"Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes","volume":"48","author":"Rodrigue","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key20141028145853201_ref1-bib28","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/hep.24248","article-title":"Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral\/emotional, and cognitive outcomes in children","volume":"53","author":"Rodrigue","year":"2011","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00004836-200603000-00009","article-title":"Social stigmatization and hepatitis C virus infection","volume":"40","author":"Zacks","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"key20141028145853201_ref1-bib30","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jhep.2010.01.033","article-title":"Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study","volume":"53","author":"Omland","year":"2010","journal-title":"J Hepatol"},{"key":"key20141028145853201_ref1-bib31","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.jpeds.2005.10.031","article-title":"The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period","volume":"148","author":"Jhaveri","year":"2006","journal-title":"J Pediatr"},{"volume-title":"Interferon alfa (Pegylated and Non-pegylated) and Ribavirin for the Treatment of Chronic Hepatitis C.","year":"2000","author":"","key":"key20141028145853201_ref1-bib32"},{"volume-title":"Peginterferon alfa and Ribavirin for the Treatment of Mild Chronic Hepatitis C.","year":"2006","author":"","key":"key20141028145853201_ref1-bib33"},{"volume-title":"Peginterferon alfa and Ribavirin for the Treatment of Chronic Hepatitis C","year":"2010","author":"","key":"key20141028145853201_ref1-bib34"},{"volume-title":"Management of Hepatitis C. A National Clinical Guideline.","year":"2006","author":"","key":"key20141028145853201_ref1-bib35"},{"key":"key20141028145853201_ref1-bib36","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/135965350400900405","article-title":"Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study","volume":"9","author":"Bruno","year":"2004","journal-title":"Antiviral Ther"},{"key":"key20141028145853201_ref1-bib37","unstructured":"Roche Products Limited. Summary of Product Characteristics \u2013 Peginterferon alfa-2a (Pegasys). European Medicines Agency; 2012. URL: www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000395\/human_med_000974.jsp&mid=WC0b01ac058001d124 (accessed 21 May 2012)."},{"key":"key20141028145853201_ref1-bib38","unstructured":"Merck Sharp & Dohme Limited. Summary of Product Characteristics \u2013 Peginterferon alfa-2b (ViraferonPeg). European Medicines Agency; 2012. URL: www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000329\/human_med_001142.jsp&mid=WC0b01ac058001d124 (accessed 21 May 2012)."},{"key":"key20141028145853201_ref1-bib39","unstructured":"Merck Sharp & Dohme Limited. Summary of Product Characteristics \u2013 Ribavirin (Rebetol). European Medicines Agency; 2012. URL: www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000246\/human_med_001017.jsp&mid=WC0b01ac058001d124 (accessed 21 May 2012)."},{"key":"key20141028145853201_ref1-bib40","unstructured":"Roche Products Limited. Summary of Product Characteristics \u2013 Ribavirin (Copegus). Electronic Medicines Compendium; 2012. URL: www.medicines.org.uk\/EMC\/medicine\/10081\/SPC\/Pegasys\u00b1135mcg\u00b1and\u00b1180mcg\u00b1\u00b1solution\u00b1for\u00b1injection\u00b1in\u00b1Pre-filled\u00b1Syringe\u00b1Pre-filled\u00b1Pen\/ (accessed 21 May 2012)."},{"issue":"17","key":"key20141028145853201_ref1-bib41","doi-asserted-by":"publisher","DOI":"10.3310\/hta15170","article-title":"Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV\/HIV co-infection: a systematic review and economic evaluation","volume":"15","author":"Hartwell","year":"2011","journal-title":"Health Technol Assess"},{"issue":"39","key":"key20141028145853201_ref1-bib42","doi-asserted-by":"crossref","DOI":"10.3310\/hta8390","article-title":"Pegylated interferon alpha 2a and 2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review","volume":"8","author":"Shepherd","year":"2004","journal-title":"Health Technol Assess"},{"key":"key20141028145853201_ref1-bib43","volume-title":"Systematic Reviews: CRD\u2019s Guidance for Undertaking Reviews in Health Care","author":"","year":"2009","edition":"3rd edn."},{"key":"key20141028145853201_ref1-bib44","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","article-title":"Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party","volume":"313","author":"Drummond","year":"1996","journal-title":"BMJ"},{"issue":"36","key":"key20141028145853201_ref1-bib45","doi-asserted-by":"crossref","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"key":"key20141028145853201_ref1-bib46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S1665-2681(19)31654-0","article-title":"Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents","volume":"9","author":"Al Ali","year":"2010","journal-title":"Ann Hepatol"},{"key":"key20141028145853201_ref1-bib47","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s12098-009-0187-x","article-title":"Pegylated alpha interferon 2B plus ribavirin in the treatment of HCV genotype 4 infection","volume":"76","author":"Ghaffar","year":"2009","journal-title":"Indian J Pediatr"},{"key":"key20141028145853201_ref1-bib48","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/INF.0b013e318159836c","article-title":"Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection","volume":"27","author":"Jara","year":"2008","journal-title":"Pediatr Infect Dis J"},{"key":"key20141028145853201_ref1-bib49","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/1740774507085445","article-title":"Design of the PEDS-C trial: pegylated interferon +\/- ribavirin for children with chronic hepatitis C viral infection","volume":"4","author":"Murray","year":"2007","journal-title":"Clin Trials"},{"key":"key20141028145853201_ref1-bib50","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/MPG.0b013e3181b99cf0","article-title":"Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon","volume":"51","author":"Narkewicz","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"key20141028145853201_ref1-bib51","first-page":"CR616","article-title":"Virologic response to treatment with Pegylated Interferon alfa-2b and Ribavirin for chronic hepatitis C in children","volume":"16","author":"Pawlowska","year":"2010","journal-title":"Med Sci Monit"},{"key":"key20141028145853201_ref1-bib52","first-page":"855A","article-title":"Virological response to treatment with pegylated interferon alfa-2b and ribavirin chronic hepatitis C in children","volume":"48","author":"Pawlowska","year":"2008","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib53","first-page":"418A","article-title":"Peginterferon alfa-2a with or without ribavirin results in minimal effect on quality of life, emotional, and cognitive outcomes: Results of the Peds-C trial","volume":"50","author":"Rodrigue","year":"2009","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib54","first-page":"1031A","article-title":"Incidence of neutropenia and impact on sustained virological response (Svr) in children and adolescents with chronic hepatitis C treated with peginterferon with or without ribavirin: the Peds-C experience","volume":"48","author":"Rosenthal","year":"2008","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib55","first-page":"418A","article-title":"Peginterferon with or without ribavirin for chronic hepatitis C in children and adolescents: final results of the Peds-C trial","volume":"48","author":"Schwarz","year":"2008","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib56","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1053\/j.gastro.2010.10.047","article-title":"The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C","volume":"140","author":"Schwarz","year":"2011","journal-title":"Gastroenterology"},{"key":"key20141028145853201_ref1-bib57","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jhep.2010.01.028","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents","volume":"52","author":"Sokal","year":"2010","journal-title":"J Hepatol"},{"key":"key20141028145853201_ref1-bib58","first-page":"392A","article-title":"Children with HCV infection show high sustained virologic response rates on peginterferon alfa-2b plus ribavirin treatment","volume":"48","author":"Wirth","year":"2008","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib59","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jhep.2010.01.016","article-title":"High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin","volume":"52","author":"Wirth","year":"2010","journal-title":"J Hepatol"},{"volume-title":"Peginterferon alfa and Ribavirin for the Treatment of Chronic Hepatitis C in Children and Young People [ID373]: Final Scope","year":"2012","author":"","key":"key20141028145853201_ref1-bib60"},{"key":"key20141028145853201_ref1-bib61","unstructured":"Schwarz KB. PEDS-C: Pegylated Interferon +\/- Ribavirin for Children with Hepatitis C. ClinicalTrials.gov study details, 2011. URL: www.clinicaltrials.gov\/ct2\/show\/NCT00100659?term=PEDS-C&rank=1 (accessed 21 May 2012)."},{"key":"key20141028145853201_ref1-bib62","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1002\/hep.25690","article-title":"Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial","volume":"56","author":"Jonas","year":"2012","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib63","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/hep.20661","article-title":"Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C","volume":"41","author":"Wirth","year":"2005","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib64","first-page":"185","article-title":"An open-label pilot study evaluating the efficacy and safety of peginterferon alfa-2a combined with ribavirin in children with chronic hepatitis C","volume":"19","author":"Zhang","year":"2005","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"key":"key20141028145853201_ref1-bib65","first-page":"319","article-title":"Treatment of chronic hepatitis C in children with pegylated interferon alpha2a and ribavirin \u2013 a multi-center study","volume":"69","author":"Sluzewski","year":"2012","journal-title":"Acta Poloniae Pharm"},{"key":"key20141028145853201_ref1-bib66","first-page":"780A","article-title":"UK experience of treatment of chronic viral hepatitis C in children and adolescents: predictors of viral response and quality of life","volume":"52","author":"Abdel-Hady","year":"2010","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib67","doi-asserted-by":"publisher","first-page":"PA403","DOI":"10.1016\/j.jval.2011.08.935","article-title":"Anti-viral treatment of chronic hepatitis C in a paediatric population: a cost-effectiveness analysis","volume":"7","author":"Mernagh","year":"2011","journal-title":"Value Health"},{"key":"key20141028145853201_ref1-bib68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00006454-200001000-00006","article-title":"Cost-effectivness analysis of different strategies of managment of chronic hepatitis C infection in children","volume":"19","author":"Sinha","year":"2000","journal-title":"Pediatr Infect Dis J"},{"volume-title":"Guide to the Methods of Technology Appraisal.","year":"2008","author":"","key":"key20141028145853201_ref1-bib69"},{"key":"key20141028145853201_ref1-bib70","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1080\/00365520902898135","article-title":"Health-related quality of life in patients with different stages of liver disease induced by hepatitis C","volume":"44","author":"Bjornsson","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"key20141028145853201_ref1-bib71","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1572-0241.2003.07332.x","article-title":"Health-state utilities and quality of life in hepatitis C patients","volume":"98","author":"Chong","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"34","key":"key20141028145853201_ref1-bib72","doi-asserted-by":"crossref","DOI":"10.3310\/hta11340","article-title":"Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis","volume":"11","author":"Thompson-Coon","year":"2007","journal-title":"Health Technol Assess"},{"volume-title":"Unit Costs of Health and Social Care 2009","year":"2010","author":"Curtis","key":"key20141028145853201_ref1-bib73"},{"volume-title":"British National Formulary","year":"2012","author":"","key":"key20141028145853201_ref1-bib74"},{"key":"key20141028145853201_ref1-bib75","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1572-0241.2003.07293.x","article-title":"Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time?","volume":"98","author":"Guido","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"key20141028145853201_ref1-bib76","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0022-3476(05)83288-3","article-title":"Comprehensive assessment of the health status of extremely low birth weight children at eight years of age: comparison with a reference group","volume":"125","author":"Saigal","year":"1994","journal-title":"J Pediatr"},{"volume-title":"Populating an Economic Model with Health State Utility Values: Moving Towards Better Practice","year":"2009","author":"Ara","key":"key20141028145853201_ref1-bib77"},{"key":"key20141028145853201_ref1-bib78","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib79","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"key20141028145853201_ref1-bib80","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"Fattovich","year":"1997","journal-title":"Gastroenterology"},{"key":"key20141028145853201_ref1-bib81","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/gut.52.3.425","article-title":"Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C","volume":"52","author":"Siebert","year":"2003","journal-title":"Gut"},{"issue":"21","key":"key20141028145853201_ref1-bib82","doi-asserted-by":"crossref","DOI":"10.3310\/hta10210","article-title":"Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation","volume":"10","author":"Wright","year":"2006","journal-title":"Health Technol Assess"},{"key":"key20141028145853201_ref1-bib83","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"key20141028145853201_ref1-bib84","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1053\/jlts.2002.31345","article-title":"Assessing health-related quality of life pre- and post-liver transplantation: a prospective multicenter study","volume":"8","author":"Ratcliffe","year":"2002","journal-title":"Liver Transpl"},{"volume-title":"UK Population Norms for EQ-5D","year":"1999","author":"Kind","key":"key20141028145853201_ref1-bib85"},{"key":"key20141028145853201_ref1-bib86","unstructured":"Department of Health. NHS Reference Costs 2010\u20132011. URL: www.dh.gov.uk\/en\/Publicationsandstatistics\/Publications\/PublicationsPolicyAndGuidance\/DH_122803 (accessed 16 December 2011)."},{"volume-title":"British National Formulary","year":"2012","author":"","key":"key20141028145853201_ref1-bib87"},{"key":"key20141028145853201_ref1-bib88","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/0952-8180(92)90111-D","article-title":"Predictors of body surface area","volume":"4","author":"Wang","year":"1992","journal-title":"J Clin Anesth"},{"key":"key20141028145853201_ref1-bib89","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1002\/hep.23504","article-title":"Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials","volume":"51","author":"Awad","year":"2010","journal-title":"Hepatology"},{"key":"key20141028145853201_ref1-bib90","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.clinthera.2010.08.009","article-title":"A comparison of peginterferon alfa-2a and alfa-2b for treatment-naive patients with chronic hepatitis C virus: a meta-analysis of randomized trials","volume":"32","author":"Zhao","year":"2010","journal-title":"Clin Ther"},{"key":"key20141028145853201_ref1-bib91","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/hep.22094","article-title":"Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial","volume":"47","author":"Goodman","year":"2008","journal-title":"Hepatology"},{"volume-title":"Peginterferon alfa and Ribavirin for the Treatment of Chronic Hepatitis C in Children and Young People Aged 3\u201317 Years: Manufacturer Submission of Evidence","year":"2012","author":"","key":"key20141028145853201_ref1-bib92"},{"key":"key20141028145853201_ref1-bib93","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/pbc.22438","article-title":"An updated follow-up of chronic hepatitis C after three decades of observation in pediatric patients cured of malignancy","volume":"55","author":"Cesaro","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"key20141028145853201_ref1-bib94","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1086\/497141","article-title":"Chronic hepatitis C in childhood: an 18-year experience","volume":"41","author":"Iorio","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key20141028145853201_ref1-bib95","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1007\/s00520-009-0763-7","article-title":"Natural course of HCV infection in childhood cancer survivors","volume":"18","author":"Fioredda","year":"2010","journal-title":"Support Care Cancer"},{"key":"key20141028145853201_ref1-bib96","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1002\/hep.510260333","article-title":"Pathology of chronic hepatitis C in children. Child Liver Study Group of Japan","volume":"26","author":"Kage","year":"1997","journal-title":"Hepatology"},{"volume-title":"Peginterferon alfa-2a and Ribavirin for the Treatment of Paediatric Chronic Hepatitis C. Manufacturer Submission of Evidence","year":"2012","author":"","key":"key20141028145853201_ref1-bib97"},{"key":"key20141028145853201_ref1-bib98","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1086\/497695","article-title":"A significant sex \u2013 but not elective cesarean section \u2013 effect on mother-to-child transmission of hepatitis C virus infection","volume":"192","author":"","year":"2005","journal-title":"J Infect Dis"},{"key":"key20141028145853201_ref1-bib99","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/lt.20793","article-title":"The natural history of hepatitis C virus in pediatric liver transplant recipients","volume":"12","author":"Barshes","year":"2006","journal-title":"Liver Transp"},{"volume-title":"Deaths Registered in England and Wales in 2010 By Cause. Statistical Bulletin","author":"","key":"key20141028145853201_ref1-bib100"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta18650\/hta18650.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta18650\/hta18650.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T14:25:13Z","timestamp":1717511113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta18650\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":100,"journal-issue":{"issue":"65","published-online":{"date-parts":[[2014,10]]}},"alternative-id":["10.3310\/hta18650"],"URL":"https:\/\/doi.org\/10.3310\/hta18650","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"type":"print","value":"1366-5278"},{"type":"electronic","value":"2046-4924"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}